What role should the UK play?

The UK has already played a leading role through the implementation of a new project led by NICE and NHSE&I, which provides a new model for researching and investing in new antibiotics.

But solving antibiotic resistance needs global leaders to develop and implement these kinds of solutions and share those with other governments around the world so that we can work #TogetherForAntibiotics.

Working in partnership is the only way we can tackle the drug resistant infections which could overwhelm health systems. The UK has also taken an early lead in this field, making antibiotic resistance a centrepiece of its agenda during its G7 Presidency.

UK Government has an ambition to lead the world in discovering new antibiotics, launching their 5-year National Action Plan to tackle antimicrobial resistance in 2019. This sets out how Britain will achieve its new 20-year vision for a world in which antibiotic resistance is contained and controlled by 2040.

The plans contain the detail for how the UK will address the market failure in antibiotics, with the NHS testing a first-of-its-kind ‘subscription-style’ payment model that will help incentivise companies to develop new drugs needed to tackle resistant infections.

Two products have been selected to be tested by the NHS, and contracts for them are expected to start in 2022. But we now need to start thinking about what new model is used for all the antibiotics that come after them.

What can patient groups do?

If you want to get involved in the ABPI’s #TogetherforAntibiotics campaign, there are lots of opportunities to collaborate.

We have partnered with patient groups and charities to co-create content highlighting the importance of antibiotics and if you’d like to work with us on creating your own bespoke imagery or video, please get in touch.

You can also read more about the issue by downloading our key messages here.